SCHEMBL21663994

SCHEMBL21663994

Fc1cccnc1C1=NCCS1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.45
ALDH1A1 P00352 3/20 0.45
ATM Q13315 1/20 0.45
LMNA P02545 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPC1 O15118 1/20 0.35
CASP3 P42574 1/20 0.35
RAB9A P51151 1/20 0.35
SENP8 Q96LD8 1/20 0.35
SENP7 Q9BQF6 1/20 0.35
SENP6 Q9GZR1 1/20 0.35
HPGD P15428 2/20 0.33
GABRG2 P18507 3/20 0.32
GABRB3 P28472 3/20 0.32
GABRA5 P31644 3/20 0.32
GABRA3 P34903 3/20 0.32
GABRA1 P14867 2/20 0.32
POLB P06746 1/20 0.32
NISCH Q9Y2I1 1/20 0.31
P2RX3 P56373 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21664089 0.79 CYP2A6 (0.42) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL21663794 0.79 MAPT (0.42) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL21664130 0.74 SMN1; SMN2 (0.41) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL28020680 0.73 LMNA (0.49) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL21664002 0.73 NISCH (0.44) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL15624391 0.72 TDP1 (0.44) MAPTLMNASMN1; SMN2GABRG2GABRB3
SCHEMBL11128734 0.71 ALDH1A1 (0.42) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL2492257 0.69 KDM4E (0.48) MAPTALDH1A1ATMLMNASMN1; SMN2
Bromide SCHEMBL2724184 0.68 KDM4E (0.46) MAPTALDH1A1ATMLMNASMN1; SMN2
SCHEMBL19815173 0.67 GABRG2 (0.37) GABRG2GABRB3GABRA5GABRA3GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound FUJIFILM CORPORATION (JP) 2022-05-03 US disclosed
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND FUJIFILM CORPORATION (JP) 2020-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040039-A1 PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND VIP, NPPA, NGLY1 MAPT 3979/4885ALDH1A1 4809/4885ATM 4555/4885
US-11319347-B2 Peptide compound and method for producing same, composition for screening use, and method for selecting peptide compound VIP, NPPA, NGLY1 MAPT 3979/4885ALDH1A1 4809/4885ATM 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.